Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
Discount pricing and poor first day defies the recent trend for floating device makers.
It takes more than a pandemic to stop medical device companies merging.
2019 was an average year for medtech M&A. 2020, not so much.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.